Aspiration Pneumonia, Malnutrition
Conditions
Brief summary
The smART+ is a comprehensive modular patient care system intended for ICU patients. The main purpose of the study is the optimization of the delivery of nutrition. The use of the smART+ Feeding tube includes a feature of facilitating correct tube placement and alerting when the tube is displaced during ongoing use. The system will automatically stop feeding if displacement is detected. If a massive reflux episode is detected by the system, a balloon located on the tube will automatically inflate and automatic GRV (Gastric Residual Volume) feature will open to prevent gastric content from regurgitating to the esophagus. In addition to tube placement, the system allows to obtain REE (Resting Energy Expenditure) measurements and calculates the optimized nutritional values required by the patient. Furthermore, the system optimizes feeding by compensating for any lost feeding time or discarded nutritional content that was discarded via the GRV (Gastric Residual Volume). Study participants will be randomly assigned to a study group: Group A- ICU patients receiving the investigational device (Treated). Group B- Control group.
Detailed description
Mechanically ventilated patients are unable to take food orally and therefore are dependent on enteral nutrition for provision of both energy and protein requirements. The conditions of ICU patients dramatically change throughout their ICU stay; diseases, like particularly sepsis, trauma and burns, cause clinically relevant increase in resting energy expenditure (REE) of between 40% - 80%, and most patients do not reach their required protein and caloric targets. The American association for Parenteral and Enteral Nutrition (ASPEN) recommends that for patients who are at high risk for malnutrition, efforts should be made to provide \>80% of the estimated or calculated energy and protein goal within 48-72 hours, starting with half the patient's calorie goal with the rate slowly increasing over time, in order to achieve the clinical benefit of enteral nutrition over the first week of hospitalization. However, studies have shown that more than 74% of ICU patients failed to receive at least 80% of their prescribed nutrition. Predictive equations (such as Harris-Benedict equation) or a simple weight-based formula (48.1% and 48.7% respectively) have therefore been the most practiced methods of determining energy needs; however, the literature clearly indicates that each equation has a large potential for error. This makes it difficult to accurately predict an individual patient's energy requirements during critical illness. In general, predictive equations estimate accurately only 50% of the time in ICU patients, leading to over or under evaluation of the nutritional needs and inducing over or underfeeding. Numerous meta-analyses have demonstrated the poor value of predictive equations variability that is increased because body weight remains a value difficult to accurately assess. To overcome the inaccuracy in determining the patient's energy consumption and the accompanying problems, the European Society for Parenteral and Enteral Nutrition (ESPEN) guidelines recommend to determine patients' REE based on indirect calorimetry or VCO2-based equation (VCO2 x 8.19). Unfortunately, this is not performed continuously during the course of enteral feeding to assess the ever-changing nutritional needs of the patient. Estimations showed that only 2% of ICUs were regularly using REE / indirect calorimetry,11 and therefore they must resort to performing a one-time calculation of the patient's energy consumption to manually calculate the caloric intake, food type and feeding rate. This study aims to assess the accuracy of the smART+ System's REE module, compared to (1) the FDA-cleared COSMED device, and (2) nutritional calculations conducted with predictive equations regularly used by the clinical staff at the site.
Interventions
Utilizing the smART+ System to provide feeding optimization to the patient
Sponsors
Study design
Eligibility
Inclusion criteria
* Males and females 18 years or older * Patient that have already been admitted to the ICU (no more than 48 hours before enrollment) * Expected to be ventilated at least 48 hours after enrollments. * Patient requires enteral feeding (by naso/oro-gastric feeding tube)
Exclusion criteria
* Pregnant women * Known anatomical anomalies of the nose, oral cavity esophagus or the stomach that may prevent/hinder the ability to insert the feeding tube
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Nutrition Optimization | 2 days-14 days | Optimization of the delivery of nutrition by the smART+ System as compared to standard of care, by automatically calculating and administering enteral feeding better than standard of care (REE or Calorimeter). The primary endpoint was the average feeding deviation between Days 2-14. Feeding deviation percentage was defined as the percentage of deviation from the nutrition target, calculated as the absolute value of 100 X (volume of nutrition delivered (mL) / the volume intended to be delivered (VTBD; mL)) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Decrease in Intensive Critical Unit Length of Stay | from admission to discharge from ICU ('ICU length of stay') | Measured from admission to Intensive Critical Unit until the decision to discharge is ordered. |
| Reduction of Number of Patients With VAE (Ventilation Associated Events) | 2 days-14 days | Ventilated associated events (VAE) was evaluated by modifications of FIO2 fraction of inspired oxygen (above .2) or PEEP Positive end-expiratory pressure (above 3 cm H20) requirements that were longer than 48 hours \[per the CDC Centers for Disease Control and Prevention definition and clinical judgment of the interpreting physician\] |
| Decrease in ICU Ventilation Days | from admission to discharge from ICU ('ICU length of stay') up to 14 days. | Evaluated by the number of hours of End-tidal CO2 from the hospital electronic records |
| Device Safety According to Occurrence or Absence of Related AE Adverse Event or SAE Serious Adverse Events | 2 days-14 days | Safe use of the entire system will be assessed based on the occurrence of device-related AE adverse event or SAE Serious Adverse Events. |
| Assessment of Urine Flow Monitoring Related to Patient Condition | 2 days-14 days | Patient lab results obtained through the hospital's electronic records will be analyzed against smART+ system urine alerts to determine if the alerts will be useful in the diagnosis |
| Convenience of Use of the System and the User Interface (by Subjective Staff Questionnaire) | Throughout the study | Subjective staff questionnaire to be completed by all personnel involved in the study, to assess usability. In order to assess this endpoint a larger sample size is required. This secondary endpoint was omitted from the study because the study enrollment was stopped after the primary endpoint of feeding efficוency was achieved (100 patients enrolled). |
| Decrease in Workload Related to Nurse Gastric Residual Volume (GRV) Time | 2 days-14 days | The change in workload could be estimated by using the estimated nursing time that was expended for GRV activities, and the amounts of GRV removed from the patient obtained through the hospital's electronic records. |
Countries
Israel
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Interventional Device - Treated Subjects connected to the investigational device smART+
smART+ System: Utilizing the smART+ System to provide feeding optimization to the patient | 50 |
| Control Group treated according to local Standard of Care. | 50 |
| Total | 100 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 1 | 0 |
| Overall Study | Patient early extubation | 1 | 3 |
| Overall Study | Patient failure nasogastric tube | 1 | 0 |
| Overall Study | Patient not required enteral feeding | 1 | 0 |
| Overall Study | Physician Decision | 1 | 0 |
Baseline characteristics
| Characteristic | Control Group | Total | Interventional Device - Treated |
|---|---|---|---|
| Age, Continuous | 62.1 years STANDARD_DEVIATION 16 | 60.7 years STANDARD_DEVIATION 16.7 | 59.4 years STANDARD_DEVIATION 17.5 |
| APACHE II Acute Physiology and Chronic Healthy Evaluation II | 22.3 units on a scale STANDARD_DEVIATION 7 | 22.4 units on a scale STANDARD_DEVIATION 6.9 | 22.4 units on a scale STANDARD_DEVIATION 6.9 |
| BMI body mass index | 29.5 KG/M^2 STANDARD_DEVIATION 8.8 | 29.3 KG/M^2 STANDARD_DEVIATION 8.1 | 29.2 KG/M^2 STANDARD_DEVIATION 7.3 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 50 Participants | 100 Participants | 50 Participants |
| Region of Enrollment Israel | 50 participants | 100 participants | 50 participants |
| Sex: Female, Male Female | 16 Participants | 27 Participants | 11 Participants |
| Sex: Female, Male Male | 34 Participants | 73 Participants | 39 Participants |
| Time to Intensive Care Unit administration | 28.3 Hours STANDARD_DEVIATION 11.4 | 26.4 Hours STANDARD_DEVIATION 11.6 | 24.5 Hours STANDARD_DEVIATION 11.7 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 3 / 50 | 3 / 50 |
| other Total, other adverse events | 35 / 50 | 39 / 50 |
| serious Total, serious adverse events | 3 / 50 | 3 / 50 |
Outcome results
Nutrition Optimization
Optimization of the delivery of nutrition by the smART+ System as compared to standard of care, by automatically calculating and administering enteral feeding better than standard of care (REE or Calorimeter). The primary endpoint was the average feeding deviation between Days 2-14. Feeding deviation percentage was defined as the percentage of deviation from the nutrition target, calculated as the absolute value of 100 X (volume of nutrition delivered (mL) / the volume intended to be delivered (VTBD; mL))
Time frame: 2 days-14 days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Interventional Device - Treated | Nutrition Optimization | 89.5 percentage of feeding efficiency | Standard Deviation 13 |
| Control Group | Nutrition Optimization | 65 percentage of feeding efficiency | Standard Deviation 18 |
Assessment of Urine Flow Monitoring Related to Patient Condition
Patient lab results obtained through the hospital's electronic records will be analyzed against smART+ system urine alerts to determine if the alerts will be useful in the diagnosis
Time frame: 2 days-14 days
Population: In order to assess this endpoint a larger sample size is required. This secondary endpoint was omitted from the study because the study enrollment was stopped after the primary endpoint of feeding efficiency was achieved (100 patients enrolled).
Convenience of Use of the System and the User Interface (by Subjective Staff Questionnaire)
Subjective staff questionnaire to be completed by all personnel involved in the study, to assess usability. In order to assess this endpoint a larger sample size is required. This secondary endpoint was omitted from the study because the study enrollment was stopped after the primary endpoint of feeding efficוency was achieved (100 patients enrolled).
Time frame: Throughout the study
Decrease in ICU Ventilation Days
Evaluated by the number of hours of End-tidal CO2 from the hospital electronic records
Time frame: from admission to discharge from ICU ('ICU length of stay') up to 14 days.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Interventional Device - Treated | Decrease in ICU Ventilation Days | 9.52 Days | Standard Deviation 7.32 |
| Control Group | Decrease in ICU Ventilation Days | 12.78 Days | Standard Deviation 8.74 |
Decrease in Intensive Critical Unit Length of Stay
Measured from admission to Intensive Critical Unit until the decision to discharge is ordered.
Time frame: from admission to discharge from ICU ('ICU length of stay')
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Interventional Device - Treated | Decrease in Intensive Critical Unit Length of Stay | 10.37 Days | Standard Deviation 7.01 |
| Control Group | Decrease in Intensive Critical Unit Length of Stay | 13.65 Days | Standard Deviation 9.16 |
Decrease in Workload Related to Nurse Gastric Residual Volume (GRV) Time
The change in workload could be estimated by using the estimated nursing time that was expended for GRV activities, and the amounts of GRV removed from the patient obtained through the hospital's electronic records.
Time frame: 2 days-14 days
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) |
|---|---|---|---|
| Interventional Device - Treated | Decrease in Workload Related to Nurse Gastric Residual Volume (GRV) Time | Max GRV per event in one day [ml/d] | 33.3941 ml/day |
| Interventional Device - Treated | Decrease in Workload Related to Nurse Gastric Residual Volume (GRV) Time | Daily total amount of GRV [ml/day] | 124.25 ml/day |
| Control Group | Decrease in Workload Related to Nurse Gastric Residual Volume (GRV) Time | Daily total amount of GRV [ml/day] | 166.10 ml/day |
| Control Group | Decrease in Workload Related to Nurse Gastric Residual Volume (GRV) Time | Max GRV per event in one day [ml/d] | 114.95 ml/day |
Device Safety According to Occurrence or Absence of Related AE Adverse Event or SAE Serious Adverse Events
Safe use of the entire system will be assessed based on the occurrence of device-related AE adverse event or SAE Serious Adverse Events.
Time frame: 2 days-14 days
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Interventional Device - Treated | Device Safety According to Occurrence or Absence of Related AE Adverse Event or SAE Serious Adverse Events | Death not related to device | 3 Participants |
| Interventional Device - Treated | Device Safety According to Occurrence or Absence of Related AE Adverse Event or SAE Serious Adverse Events | Adverse event related to device | 0 Participants |
| Control Group | Device Safety According to Occurrence or Absence of Related AE Adverse Event or SAE Serious Adverse Events | Adverse event related to device | 0 Participants |
| Control Group | Device Safety According to Occurrence or Absence of Related AE Adverse Event or SAE Serious Adverse Events | Death not related to device | 3 Participants |
Reduction of Number of Patients With VAE (Ventilation Associated Events)
Ventilated associated events (VAE) was evaluated by modifications of FIO2 fraction of inspired oxygen (above .2) or PEEP Positive end-expiratory pressure (above 3 cm H20) requirements that were longer than 48 hours \[per the CDC Centers for Disease Control and Prevention definition and clinical judgment of the interpreting physician\]
Time frame: 2 days-14 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Interventional Device - Treated | Reduction of Number of Patients With VAE (Ventilation Associated Events) | 1 Participants |
| Control Group | Reduction of Number of Patients With VAE (Ventilation Associated Events) | 5 Participants |